fluticasone

Disclaimer to the Online Edition

This Manual has been designed for use in the NICU at London Health Sciences Centre (LHSC), London, Ontario, Canada, and represents clinical practice at this institution. The information contained within the Manual may not be applicable to other centres. If users of this Manual are not familiar with a drug, it is recommended that the official monograph be consulted before it is prescribed and administered. Any user of this information is advised that the contributors, Editor and LHSC are not responsible for any errors or omissions, and / or any consequences arising from the use of the information in this Manual.

fluticasone

Indication

  • An inhaled corticosteroid used in the treatment of bronchopulmonary dysplasia

Dosage Guidelines

  • 125 – 250 micrograms (1 or 2 puffs) INH q12h

Administration

  • Inhaler must be primed prior to first use – remove the mouthpiece, shake canister well for 5 seconds, then actuate the inhaler.  Shake and actuate a second time.
  • Shake canister well for 5 seconds before each spray
  • Respiratory Therapist to administer each dose with an aerochamber
  • Rinse or swab mouth with water after each administration

Adverse Effects

  • Throat irritation
  • Upper respiratory infection
  • Oral candidiasis

Comments

  • Monitor mouth and perineum for candidiasis
  • Onset: within 24 hours
  • Maximum effect: 1 to 2 weeks

Supplied As

  • 125 microgram/puff  inhalation aerosol  metered dose inhaler

References

LexiComp Pediatric and Neonatal